So-Yeon Kang, Ge Bai, Michael J DiStefano, Mariana P Socal, Farah Yehia, Gerard F Anderson
{"title":"Comparative Approaches to Drug Pricing.","authors":"So-Yeon Kang, Ge Bai, Michael J DiStefano, Mariana P Socal, Farah Yehia, Gerard F Anderson","doi":"10.1146/annurev-publhealth-040119-094305","DOIUrl":null,"url":null,"abstract":"<p><p>The United States relies primarily on market forces to determine prices for drugs, whereas most other industrialized countries use a variety of approaches to determine drug prices. Branded drug companies have patents and market exclusivity periods in most industrialized countries. During this period, pharmaceutical companies are allowed to set their list price as high as they prefer in the United States owing to the absence of government price control mechanisms that exist in other countries. Insured patients often pay a percentage of the list price, and cost sharing creates some pressure to lower the list price. Pharmacy benefit managers negotiate with drug companies for lower prices by offering the drug company favorable formulary placement and fewer utilization controls. However, these approaches appear to be less effective, compared with other countries' approaches to containing branded drug prices, because prices are substantially higher in the United States. Other industrialized countries employ various forms of rate setting and price regulation, such as external reference pricing, therapeutic valuation, and health technology assessment to determine the appropriate price.</p>","PeriodicalId":50752,"journal":{"name":"Annual Review of Public Health","volume":"41 ","pages":"499-512"},"PeriodicalIF":21.4000,"publicationDate":"2020-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1146/annurev-publhealth-040119-094305","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Review of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-publhealth-040119-094305","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/12/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 14
Abstract
The United States relies primarily on market forces to determine prices for drugs, whereas most other industrialized countries use a variety of approaches to determine drug prices. Branded drug companies have patents and market exclusivity periods in most industrialized countries. During this period, pharmaceutical companies are allowed to set their list price as high as they prefer in the United States owing to the absence of government price control mechanisms that exist in other countries. Insured patients often pay a percentage of the list price, and cost sharing creates some pressure to lower the list price. Pharmacy benefit managers negotiate with drug companies for lower prices by offering the drug company favorable formulary placement and fewer utilization controls. However, these approaches appear to be less effective, compared with other countries' approaches to containing branded drug prices, because prices are substantially higher in the United States. Other industrialized countries employ various forms of rate setting and price regulation, such as external reference pricing, therapeutic valuation, and health technology assessment to determine the appropriate price.
期刊介绍:
The Annual Review of Public Health has been a trusted publication in the field since its inception in 1980. It provides comprehensive coverage of important advancements in various areas of public health, such as epidemiology, biostatistics, environmental health, occupational health, social environment and behavior, health services, as well as public health practice and policy.
In an effort to make the valuable research and information more accessible, the current volume has undergone a transformation. Previously, access to the articles was restricted, but now they are available to everyone through the Annual Reviews' Subscribe to Open program. This open access approach ensures that the knowledge and insights shared in these articles can reach a wider audience. Additionally, all the published articles are licensed under a CC BY license, allowing users to freely use, distribute, and build upon the content, while giving appropriate credit to the original authors.